Lisa Cook sues Trump over firing attempt, emergency hearing set
On Monday, Goldman Sachs reaffirmed its Buy rating on Eli Lilly shares (NYSE:LLY) with a price target of $888.00. Currently trading at $884.54, the stock has shown remarkable momentum with an 8.13% gain over the past week. According to InvestingPro data, analyst targets range from $650 to $1,190, with a strong consensus recommendation of 1.59 (Buy). The firm’s analyst expects Eli Lilly to report earnings on May 1, in line with the recent trends observed in the pharmaceutical sector, including tariff and policy discussions. Eli Lilly is anticipated to show a solid performance from its tirzepatide franchise, which includes Mounjaro and Zepbound, after a previous uneven track record.
The analyst projects around $6.0 billion in sales for tirzepatide, aligning with the Visible Alpha consensus. This projection comes as Eli Lilly demonstrates strong financial performance, with revenue growing 32% year-over-year to $45 billion and maintaining an impressive gross profit margin of 81.3%. While assessing the first quarter of 2025, the focus is likely to shift to Eli Lilly’s obesity franchise, where the company has been establishing its dominance, particularly in the GLP-1 injectable market. Additionally, attention is drawn to the oral obesity pill market following the ACHIEVE-1 study’s positive outcome for orforglipron in Type 2 diabetes patients.
Investors are looking forward to further details ahead of the complete ACHIEVE-1 study results, expected to be presented at the American Diabetes Association (ADA) conference in June. The upcoming ATTAIN-1 trial, slated for the third quarter of 2025, is also under the spotlight as it will be the first to reveal the efficacy of orforglipron in treating obesity, marking a pivotal moment in the oral obesity treatment arena. For deeper insights into Eli Lilly’s financial health and growth prospects, InvestingPro subscribers can access comprehensive research reports and 16 additional ProTips that provide valuable context for investment decisions.
In other recent news, Eli Lilly has been the focus of several analyst assessments and strategic developments. HSBC downgraded Eli Lilly’s stock from Buy to Reduce, setting a new price target of $700, citing a reassessment of the company’s weighted average cost of capital. Meanwhile, Cantor Fitzgerald maintained an Overweight rating with a $975 price target, expressing confidence in Eli Lilly’s growth prospects in the obesity market, particularly with its GLP-1 receptor agonists. Bernstein also reiterated an Outperform rating, setting a $1,100 price target, highlighting Eli Lilly’s strategic moves to expand its manufacturing capabilities in the U.S.
Furthermore, Cantor Fitzgerald noted Eli Lilly’s strong performance driven by positive clinical data, including the success of the orforglipron ACHIEVE-1 trial and increased prescriptions for its diabetes drug, Zepbound. BMO Capital Markets supported Eli Lilly with an Outperform rating and a $900 price target, emphasizing the company’s preparation for the launch of Orforglipron, a treatment for Type 2 Diabetes. Eli Lilly’s commitment to expanding its inventory and manufacturing capabilities signals readiness for the anticipated 2026 launch of Orforglipron.
These recent developments reflect varied analyst perspectives on Eli Lilly’s future, with some expressing cautious optimism and others maintaining strong confidence in the company’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.